Barclays
AKRO

Barclays’s Akero Therapeutics AKRO Stock Holding History

Barclays’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-208,400
Closed -$10.5M – 5214
2023
Q3 		$10.5M Buy
+208,400
New +$9.7M 0.01% 978

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's AKRO Position: Q4 2025 in Review

Barclays sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 487,230 shares — an estimated $23.1M sold.

Barclays first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $28.5M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Barclays reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 487,230 Akero Therapeutics shares in Q4 2025, an estimated $23.1M.
  • Barclays first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
  • Barclays's Akero Therapeutics position peaked at $28.5M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.